Tiziana Life Sciences (TLSA) Competitors $1.51 +0.02 (+1.34%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.01 (+0.99%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. TRVI, ANAB, IMTX, DAWN, MRVI, AUTL, STOK, URGN, PHAT, and RLAYShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Maravai LifeSciences (MRVI), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Its Competitors Trevi Therapeutics AnaptysBio Immatics Day One Biopharmaceuticals Maravai LifeSciences Autolus Therapeutics Stoke Therapeutics Urogen Pharma Phathom Pharmaceuticals Relay Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has more risk & volatility, TLSA or TRVI? Tiziana Life Sciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Does the media favor TLSA or TRVI? In the previous week, Trevi Therapeutics had 7 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Trevi Therapeutics and 1 mentions for Tiziana Life Sciences. Trevi Therapeutics' average media sentiment score of 0.55 beat Tiziana Life Sciences' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in TLSA or TRVI? 95.8% of Trevi Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is TLSA or TRVI more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Trevi Therapeutics N/A -58.41%-52.52% Do analysts recommend TLSA or TRVI? Trevi Therapeutics has a consensus price target of $20.88, suggesting a potential upside of 238.33%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30 Which has preferable earnings and valuation, TLSA or TRVI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/ATrevi TherapeuticsN/AN/A-$47.91M-$0.45-13.71 SummaryTrevi Therapeutics beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.10M$2.90B$5.51B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E RatioN/A21.0128.0520.15Price / SalesN/A294.68438.14127.85Price / CashN/A41.8337.0657.97Price / Book37.757.868.125.62Net Income-$11.86M-$54.95M$3.16B$248.50M7 Day Performance-3.82%6.24%4.40%5.54%1 Month Performance6.34%5.70%4.09%7.52%1 Year Performance86.19%8.08%34.53%22.06% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.8158 of 5 stars$1.51+1.3%N/A+81.6%$174.10MN/A0.008News CoveragePositive NewsTRVITrevi Therapeutics3.2488 of 5 stars$5.95flat$20.88+250.8%+115.4%$697.89MN/A-13.2220ANABAnaptysBio2.287 of 5 stars$23.45-1.3%$42.38+80.7%-4.8%$697.79M$91.28M-4.84100IMTXImmatics3.1571 of 5 stars$5.53-3.2%$14.67+165.2%-52.6%$694.05M$168.65M-32.53260DAWNDay One Biopharmaceuticals1.7048 of 5 stars$6.63-2.5%$30.57+361.1%-55.3%$689.27M$131.16M-9.3460MRVIMaravai LifeSciences3.6942 of 5 stars$2.60-2.6%$6.64+155.3%-62.4%$679.94M$259.18M-2.28610News CoverageAUTLAutolus Therapeutics2.1435 of 5 stars$2.26-4.6%$9.32+312.4%-36.7%$630.76M$10.12M-2.57330STOKStoke Therapeutics3.8846 of 5 stars$11.69+1.8%$23.20+98.5%-7.2%$626.77M$36.56M14.80100URGNUrogen Pharma4.5377 of 5 stars$13.49-0.7%$32.86+143.6%-14.8%$626.14M$90.40M-4.24200Analyst ForecastGap UpPHATPhathom Pharmaceuticals3.3195 of 5 stars$8.66-2.9%$17.50+102.1%-13.5%$622.74M$55.25M-1.65110RLAYRelay Therapeutics2.5453 of 5 stars$3.55-2.2%$17.67+397.7%-44.6%$622.34M$10.01M-1.59330 Related Companies and Tools Related Companies TRVI Competitors ANAB Competitors IMTX Competitors DAWN Competitors MRVI Competitors AUTL Competitors STOK Competitors URGN Competitors PHAT Competitors RLAY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
